The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans
Open accessAbstract
The pharmacokinetic profile of UK-49,858 (fluconazole), a novel triazole antifungal agent which is being developed for oral and intravenous use, was determined in mice, rats, dogs, and humans. Comparative data following oral and intravenous administration showed that bioavailability was essentially complete in all four species. Peak concentrations in plasma of drug normalized to a 1-mg/kg dose level following oral administration, were relatively high: 0.7, 0.6, 1.1, and 1.4 micrograms/ml in mice, rats, dogs, and humans, respectively. The volumes of distribution ranged between 1.1 liter/kg in mice and 0.7 liter/kg in humans, which are approximate to the values for total body water. Whole body autoradiography studies in mice following intravenous administration of [14C]UK-49,858 demonstrated that the drug was evenly distributed throughout the tissues, including the central nervous system and the gastrointestinal tract. Plasma protein binding was low (11 to 12%) in all species. Marked species differences were observed in elimination half-lives, with mean values of 4.8, 4.0, 14, and 22 h in mice, rats, dogs, and humans, respectively. The major route of elimination of the drug was renal clearance, with about 70% of the dose being excreted unchanged in the urine in each species. Studies with [14C]UK-49,858 on metabolism and excretion (intravenous and oral) in mice and dogs showed that about 90% of the dose was recovered as unchanged drug in urine and feces, confirming the metabolic stability of the drug. This pharmacokinetic profile is markedly different from that of imidazole antifungal drugs and undoubtedly contributes to the excellent efficacy of UK-49,858 in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gibaldi, M., & Perrier, D. (1982) · CRC Press eBooks · doi:10.1201/b14095 · Cited by 4,093
Studies on the distribution and fate of S35-labelled benzylpenicillin in the body.
Ullberg, S. (1954) · PubMed · Cited by 676
Econazole: A Review of its Antifungal Activity and Therapeutic Efficacy
Heel, R. C., Brogden, R. N., Speight, T. M., & Avery, G. S. (1978) · Drugs · doi:10.2165/00003495-197816030-00001 · Cited by 296
Disposition of ketoconazole, an oral antifungal, in humans
Brass, C., Galgiani, J. N., Blaschke, T. F., Defelice, R., O'Reilly, R. A., & Stevens, D. A. (1982) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.21.1.151 · Cited by 210
Clinical Pharmacokinetics of Systemic Antifungal Drugs
Daneshmend, T. K., & Warnock, D. W. (1983) · Clinical Pharmacokinetics · doi:10.2165/00003088-198308010-00002 · Cited by 177
Richardson, K., Brammer, K. W., Marriott, M. S., & Troke, P. F. (1985) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.27.5.832 · Cited by 166
Ketoconazole, an oral antifungal: laboratory and clinical assessment of imidazole drugs
Borelli, D., Bran, J. L., Fuentes, J., Legendre, R., Leiderman, E. A., Levine, H. B., Restrepo-M., A., & Stevens, D. A. (1979) · Postgraduate Medical Journal · doi:10.1136/pgmj.55.647.657 · Cited by 146
Heel, R. C., Brogden, R. N., Pakes, G. E., Speight, T. M., & Avery, G. S. (1980) · Drugs · doi:10.2165/00003495-198019010-00002 · Cited by 117
Pharmacokinetics of ketoconazole in normal subjects
Daneshmend, T. K., Warnock, D. W., Turner, A., & Roberts, C. J. (1981) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/8.4.299 · Cited by 87
Ketoconazole in the Management of Fungal Disease
Domer, J. E. (1982) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1982.31.604 · Cited by 86
Cited by
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Grant, S. M., & Clissold, S. P. (1990) · Drugs · doi:10.2165/00003495-199039060-00006 · Cited by 661
Oral Azole Drugs as Systemic Antifungal Therapy
Wood, A. J. J., Como, J. A., & Dismukes, W. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401273300407 · Cited by 596
Azole antifungal agents: Emphasis on new triazoles
Saag, M. S., & Dismukes, W. E. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.1.1 · Cited by 474
History of the development of azole derivatives
Maertens, J. A. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00841.x · Cited by 475
Brüggemann, R. J. M., Alffenaar, J. C., Blijlevens, N. M. A., Billaud, E. M., Kosterink, J. G. W., Verweij, P. E., & Burger, D. M. (2009) · Clinical Infectious Diseases · doi:10.1086/598327 · Cited by 457
Pharmacokinetics and Tissue Penetration of Fluconazole in Humans
Brammer, K. W., Farrow, P. R., & Faulkner, J. K. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_3.s318 · Cited by 429
The Clinical Pharmacokinetics of Itraconazole: An Overview
Heykants, J., Van Peer, A., Van de Velde, V., Van Rooy, P., Meuldermans, W., Lavrijsen, K., Woestenborghs, R., Van Cutsem, J., & Cauwenbergh, G. (1989) · Mycoses · doi:10.1111/j.1439-0507.1989.tb02296.x · Cited by 404
Overview of medically important antifungal azole derivatives
Fromtling, R. A. (1988) · Clinical Microbiology Reviews · doi:10.1128/cmr.1.2.187 · Cited by 398
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Antifungal agents: An overview. Part I
Gupta, A. K., Sauder, D. N., & Shear, N. H. (1994) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(08)81495-8 · Cited by 369
Candida and Oral Candidosis: A Review
Scully, C., EI-Kabir, M., & Samaranayake, L. P. (1994) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/10454411940050020101 · Cited by 364
THE DISPOSITION OF VORICONAZOLE IN MOUSE, RAT, RABBIT, GUINEA PIG, DOG, AND HUMAN
Roffey, S. J., Cole, S., Comby, P., Gibson, D., Jezequel, S. G., Nedderman, A. N. R., Smith, D. A., Walker, D. K., & Wood, N. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.6.731 · Cited by 330
Validation of a Rapid Equilibrium Dialysis Approach for the Measurement of Plasma Protein Binding
Waters, N. J., Jones, R., Williams, G., & Sohal, B. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21317 · Cited by 310
Systemic Antifungal Agents: Drug Interactions of Clinical Significance
Albengres Herv??, E., Lou??, L., & Tillement, J.-P. (1998) · Drug Safety · doi:10.2165/00002018-199818020-00001 · Cited by 280
Clinical Pharmacokinetics of Fluconazole
Debruyne, D., & Ryckelynck, J.-P. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324010-00002 · Cited by 255
COMPARISON OF FLUCONAZOLE AND KETOCONAZOLE FOR OROPHARYNGEAL CANDIDIASIS IN AIDS
De Wit, S., Goossens, H., Weerts, D., & Clumeck, N. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92572-5 · Cited by 199
Andes, D., & van Ogtrop, M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.9.2116 · Cited by 192
Warrilow, A. G. S., Hull, C. M., Parker, J. E., Garvey, E. P., Hoekstra, W. J., Moore, W. R., Schotzinger, R. J., Kelly, D. E., & Kelly, S. L. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03707-14 · Cited by 173
Hata, K., Horii, T., Miyazaki, M., Watanabe, N.-A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-11 · Cited by 149
Safety and pharmacokinetics of fluconazole in children with neoplastic diseases
Lee, J. W., Seibel, N. L., Amantea, M., Whitcomb, P., Pizzo, P. A., & Walsh, T. J. (1992) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)81975-4 · Cited by 120
Surgical and long-term antifungal therapy for fungal prosthetic valve endocarditis
Muehrcke, D. D., Lytle, B. W., & Cosgrove, D. M. (1995) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(95)00469-2 · Cited by 110
Fischman, A. J., Alpert, N. M., Livni, E., Ray, S., Sinclair, I., Callahan, R. J., Correia, J. A., Webb, D., Strauss, H. W., & Rubin, R. H. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.6.1270 · Cited by 93
“In addition, because fluconazole undergoes minimal metabolism in vivo (>90% of administered drug is excreted intact in the urine and feces), measurements of radioactivity in tissues and blood accurately reflect concentrations of intact drug (11, 12, 15, 33).”
Fisher, M. A., Shen, S. H., Haddad, J., & Tarry, W. F. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.9.1443 · Cited by 81
Van t Wout, J. W., Mattie, H., & van Furth, R. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.2.147 · Cited by 72
Garvey, E. P., Sharp, A. D., Warn, P. A., Yates, C. M., & Schotzinger, R. J. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky242 · Cited by 39
Metadata
- Authors
- Humphrey, M. J., Jevons, S., & Tarbit, M. H.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1985-11
- Volume
- 28
- Issue
- 5
- Pages
- 648-653
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2080721443
- Cited by
- 365
- References
- 12
- FWCI
- 12.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.